Back to Journals » ClinicoEconomics and Outcomes Research » Volume 5
Original Research
![Noteworthy comment: Survival and best supportive care costs for patients with metastatic renal cell carcinoma (mRCC) after stopping therapy are poorly characterized yet an important aspect of patient care. This study examined survival and costs associated with BSC after 1 or 2 lines of mRCC therapy](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
11,719 | Dovepress* | 10,161+ | 1,796 | 11,957 | |
PubMed Central* | 1,558 | 394 | 1,952 | ||
Totals | 11,719 | 2,190 | 13,909 | ||
*Since 9 July 2013 +Since July 2016 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
4 | 0 | 0 | 0 | 2 | 2 |
View citations on PubMed and Google Scholar